To develop evidence-based clinical algorithms for community acquired-acute respiratory tract infections CA-ARTI and assess the diagnostic accuracy and the clinical utility of point-of-care tests (POCT) for specific groups of patients, clinical findings, and settings
To develop evidence-based URS’s to support future development and implementation of rapid diagnostics to reduce antimicrobial resistance (AMR) for CA-ARTI, and to refine the methods and processes to make them applicable to POC diagnostic developments for other infectious disease indications
To create a technical roadmap that incorporates recommendations for short- and long-term goals to help companies and research institutions prioritize investment decisions in the field of CA-ARTI diagnostics.
https://www.value-dx.eu/wp-content/uploads/2019/07/shutterstock_1030079398.jpg40006000Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-04-21 09:36:392021-04-21 09:36:39VALUE-Dx investigates HTA, Reimbursement and Pricing of Diagnostic Tests for CA-ARTI
https://www.value-dx.eu/wp-content/uploads/2021/04/Stethoscope-and-laptop-scaled.jpg17072560Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-04-01 08:19:092021-04-01 08:20:35Funding models and health economics of diagnostics
https://www.value-dx.eu/wp-content/uploads/2020/06/Antibiotic-pills-Hand-Converted.jpg24822481Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-03-31 07:17:282021-03-31 07:18:42Enhancing the quality of antibiotic prescribing for CA-ARTI in Emergency Rooms through ADEQUATE trial
https://www.value-dx.eu/wp-content/uploads/2019/07/shutterstock_457866949.jpg38405760Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-03-30 13:23:232021-04-01 07:34:54PRUDENCE trial will start in the summer of 2021